Managing Acute Toxicities of CAR T-cell Therapy

In this episode, we discuss the management of acute toxicities of CAR T-cell therapy, including CRS, ICANS, and HLH with Dr. Michael Jain from Moffitt Cancer Center.Here are some of the key articles we discussed:1. “How I treat refractory CRS and ICANS after CAR T-cell therapy”.      https://pubmed.ncbi.nlm.nih.gov/36989488/ 2. CAR-HEMATOTOX score:     https://pubmed.ncbi.nlm.nih.gov/34166502/ 3. “How I treat cytopenias after CAR T-cell therapy”.     https://pubmed.ncbi.nlm.nih.gov/36800563/ 4. Immune Effector Cell-Associated HLH-Like Syndrome (ASTCT):    https://pubmed.ncbi.nlm.nih.gov/36906275/ 5. ASTCT consensus grading for CRS and ICANS:    https://pubmed.ncbi.nlm.nih.gov/30592986/6. Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy:    https://pubmed.ncbi.nlm.nih.gov/35696759/ 7. Modified EASIX score for predicting CRS and neurotoxicity:    https://pubmed.ncbi.nlm.nih.gov/34432870/